Mesothelioma

Lawdragon Names Two Dean Omar Branham Shirley Partners as Top Plaintiff Consumer Lawyers

Retrieved on: 
Wednesday, February 28, 2024
Legal, Professional Services, LLP, Union Carbide, Catastrophic injury, Mesothelioma, Personal injury, Property management

Dean Omar Branham Shirley LLP is pleased to announce that name partners Jessica Dean and Amin Omar have been named to Lawdragon’s 500 Leading Plaintiff Consumer Lawyers for 2024.

Key Points: 
  • Dean Omar Branham Shirley LLP is pleased to announce that name partners Jessica Dean and Amin Omar have been named to Lawdragon’s 500 Leading Plaintiff Consumer Lawyers for 2024.
  • “It is an honor to be named along with some of the best attorneys in the nation,” said Ms. Dean.
  • “Our whole team is proud to have the firm partners on Lawdragon’s list,” said Trey Branham .
  • Dean Omar Branham Shirley, LLP, is a nationally recognized trial firm that handles cases across the country for individuals who have suffered catastrophic injuries or have died as a result of irresponsible conduct of others.

Verismo Therapeutics Announces Opening of Second Clinical Site for STAR-101 Phase 1 Trial

Retrieved on: 
Thursday, March 7, 2024
Mesothelioma, MD Anderson Cancer Center, Patient, Ovarian cancer, Therapy, Monroe Dunaway Anderson, Verismo, Entrepreneurship, University, Pharmaceutical industry

PHILADELPHIA, March 7, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR-T company developing the novel KIR-CAR platform technology, today announced that it has activated a second clinical site for its STAR-101 Phase 1 clinical trial at The University of Texas MD Anderson Cancer Center.

Key Points: 
  • STAR-101 is a multi-center clinical trial designed to evaluate Verismo Therapeutic's lead candidate, SynKIR™-110, for the treatment of mesothelin-overexpressing ovarian cancer, malignant pleural mesothelioma, and cholangiocarcinoma.
  • "This milestone marks the steady progress towards our goal of bringing SynKIR™-110 to as many patients as possible," said Dr. Bryan Kim, Co-Founder and CEO of Verismo Therapeutics.
  • Verismo has previously announced that SynKIR™-110 received Orphan Drug Designation and Fast Track Designation for the treatment of mesothelin-expressing mesotheliomas.
  • For more information about the STAR-101 clinical trial, please visit ClinicalTrials.gov NCT05568680 .

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Glioblastoma, NSCLC, Diabetes, Lung, Lung cancer, Metabolism, EGFR, Osteosarcoma, MD, Neoplasm, FDA, Cancer, Glycolysis, Food, Growth, Anaplastic lymphoma kinase, Pembrolizumab, AACR, Cell, Apoptosis, Date, Osimertinib, Agonal respiration, Mitochondrion, Breast, University, Nanoparticle, Food and Drug Administration, NPRL2, Patient, ATP, Clinical trial, Gene, Disease, TUSC2, Trial of the century, Mesothelioma, Research, ALK, Vaccine

AUSTIN, Texas, March 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California. The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.

Key Points: 
  • The collaborators will present positive preclinical data from studies of its lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), as well as NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.
  • In this humanized mouse model, researchers investigated the anti-tumor immune responses to NPRL2 gene therapy in pembrolizumab resistant KRAS/STK11mt NSCLC.
  • "Today's bolus of compelling data validates the potential of REQORSA and the ONCOPREX Delivery System as innovative cancer treatments.
  • We look forward to continuing to evaluate the ONCOPREX Delivery System using both REQORSA and NPRL2 as potential treatments for lung cancer."

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
WBC, WRN, Lung cancer, RNA, Malignancy, Microsatellite instability, Proteome, Intellectual property, MMR, MPN, Glioblastoma, Neoplasm, Splenomegaly, DMPK, Phosphorylation, HDAC, STAT5, RNA-Seq, WES, Standard of care, Therapy, RecQ helicase, Phenotype, Ruxolitinib, DNA, DNA repair, Pancreatic serous cystadenoma, CDKN2A, Cancer, CRC, PIM, Arginine, MTA, Abstract, PDC, MTAP, Colorectal cancer, CRISPR, PV, MF, MSI-H, Cell, JAK, DNA mismatch repair, Medicine, Patient, Gene, PRMT5, Haematopoiesis, Mesothelioma, Pharmaceutical industry

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Multimedia, Mesothelioma, Malignancy, Research, Disease, Patient, Lung, SOC, Pleural cavity, MPE, RSO, Drainage, Malignant pleural effusion, Cancer, Pharmaceutical industry

The research and clinical teams are investigating RSO-021 anticancer activity in patients with malignant pleural mesothelioma and metastatic disease to the lung.

Key Points: 
  • The research and clinical teams are investigating RSO-021 anticancer activity in patients with malignant pleural mesothelioma and metastatic disease to the lung.
  • (Photo: Dan Ryan)
    Malignant pleural effusion (MPE) is the build up of fluid in the lining membrane (pleura) of the lungs.
  • RSO’s novel, investigational anti-cancer treatment, RSO-021, is administered weekly directly into the pleural space following MPE drainage via an indwelling pleural catheter.
  • “Commencing the Phase 2 portion of our trial presents a major milestone for patients and their caregivers.”

Orphan designation: paclitaxel obaluronate Treatment of malignant mesothelioma, 25/02/2023 Positive

Retrieved on: 
Sunday, February 4, 2024
COMP, IRIS, European Commission, Paclitaxel, Committee, Patient, Mesothelioma, EMA, Pharmaceutical industry

Key facts

Key Points: 
  • Key facts
    - Active substance
    - paclitaxel obaluronate
    - Intended use
    - Treatment of malignant mesothelioma
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/23/2807
    - Date of designation
    - Sponsor
    Fidia Farmaceutici S.p.A.
  • Patients' organisations
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Legal-Bay Pre-Settlement Funding Reports Johnson & Johnson Talc Powder Settlement of $700MM with 40 States Nationwide

Retrieved on: 
Monday, January 22, 2024
Hail Mary, Health, Injury, Cancer, Fraud, Inferior vena cava, Talc, Mesothelioma, Johnson & Johnson, Bankruptcy, Ovarian cancer, Starch, Personal injury, Asbestos, Public opinion, J&J, Insurance

TRENTON, N.J., Jan. 22, 2024 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that Johnson & Johnson has agreed to a $700MM settlement with various state regulators across the country.  J&J has agreed to over $300MM above the $400MM that the company had reserved for this particular case. This first major settlement comes in conjunction with a dispute with its own shareholders, including a large fund in San Diego that determined J&J's concealment is tantamount to securities fraud – an opinion which a New Jersey Judge recently certified.

Key Points: 
  • TRENTON, N.J., Jan. 22, 2024 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that Johnson & Johnson has agreed to a $700MM settlement with various state regulators across the country.
  • J&J attempted a bankruptcy filing and a $9 billion offering to resolve that litigation, but the amount was rejected as unlawful.
  • The proposal by J&J would essentially provide the average settlement amount of each talc case to be approximately $150K per—a figure woefully short considering the severity of the victims' injuries.
  • Their loan for settlement funding programs are designed to provide immediate cash in advance of a plaintiff's anticipated monetary award.

Compass Therapeutics Provides Corporate Update

Retrieved on: 
Friday, January 5, 2024
Patient, CRC, Stage 2, IND, FDA, BTC, Research and development, PD-1, DLL4, CD137, PET, Melanoma, MD, Doctor of Philosophy, Therapy, Mesothelioma, Paclitaxel, Carcinoma, SCLC, Safety, Development, NSCLC, PD-L1, Pharmaceutical industry

As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.

Key Points: 
  • As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.
  • Effective January 9, 2024, Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and Chief Executive Officer will transition to President of Research and Development and be appointed Vice Chair of the Compass board of directors.
  • BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported a business update.
  • Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and current Chief Executive Officer will transition to President of Research and Development and assume the role of Vice Chair of the Compass board of directors.

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

Retrieved on: 
Wednesday, January 3, 2024
Mesothelioma, Therapeutic index, Doctor of Science, Food, Survival, Lymphoma, Bone marrow, BLA, Ovarian cancer, GPS, MRD, FDA, Type, CMC, CR2, MD, Nivolumab, WT1, Clinical trial, SLS, Acute myeloid leukemia, Patient, Safety, PTCL, AML, Pembrolizumab, Pharmaceutical industry

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and will host a corporate webinar at 8:30 am ET.

Key Points: 
  • “2023 was a very productive year for SELLAS,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.
  • Dr. Stergiou continued: “We hope to build on this excellent progress and look forward to multiple clinical milestones that have the potential to create significant value for our shareholders.
  • Meaningful cell killing activity, defined as ≥50% reduction in blasts in the bone marrow, was observed at several dose levels.
  • This study is fully funded by the Company’s partner for SLS009, GenFleet Therapeutics (Shanghai), Inc. and is being conducted in China.

Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth

Retrieved on: 
Friday, December 22, 2023
Mesothelioma, Workforce, Leiomyosarcoma, Hepatocellular carcinoma, Acquisition, Semaglutide, MIT, Diabetes, Chemical engineering, SAN, Biologics license application, HCC, Glioblastoma, Dicarboxylic acid, Doctor of Philosophy, GBM, LMS, Growth, Escherichia coli, BLA

TAIPEI, Taiwan and SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to 100%.

Key Points: 
  • TAIPEI, Taiwan and SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to 100%.
  • Additionally, Dr. Steve Hsu, Chairman of Genovior Biotech Corporation, has been appointed as the CEO of Polaris Group.
  • These two highly prospective product lines will serve as the dual engines propelling Polaris Group's future growth.
  • Consequently, Genovior Biotech fills critical gaps for Polaris Group, providing not just high-quality manufacturing capabilities but also a substantial entry into the market for peptide products.